Acute Limb Ischemia

Ischemic Cascade and Tissue Damage

• Acute oxygen deprivation leads to immediate cessation of aerobic metabolism and ATP depletion within minutes. Muscular tissue becomes acidotic and hypoxic, initiating anaerobic metabolism that produces lactate accumulation and intracellular edema.
• Cellular injury mechanisms include Na+/K+-ATPase pump failure, leading to sodium influx, cellular swelling, and loss of cellular integrity. Calcium influx triggers activation of proteases and phospholipases, causing mitochondrial dysfunction and apoptosis.
• Reperfusion injury paradoxically causes additional damage upon restoration of blood flow through generation of reactive oxygen species (ROS), neutrophil infiltration, and complement activation via the alternative pathway, worsening tissue damage beyond the initial ischemic insult.

Microvascular and Thrombotic Changes

• Thrombosis propagation occurs through platelet aggregation and fibrin deposition at the site of arterial occlusion, with thrombin generation amplifying clot formation through feedback mechanisms.
• Endothelial dysfunction manifests as increased vascular permeability, expression of adhesion molecules (ICAM-1, VCAM-1), and release of prothrombotic substances including tissue factor and von Willebrand factor.
• No-reflow phenomenon develops as capillary beds become obstructed by swollen endothelial cells and trapped red blood cells, preventing adequate perfusion even after epicardial vessel recanalization.

Systemic Complications

• Rhabdomyolysis from necrotic skeletal muscle releases myoglobin and intracellular contents (potassium, phosphate, uric acid) into systemic circulation, causing acute tubular necrosis, hyperkalemia, and cardiac arrhythmias.
• Acidosis and hyperkalemia from ischemic tissue produce severe electrolyte derangements that can cause sudden cardiac arrest, particularly upon reperfusion when potassium mobilizes from damaged cells.
• Systemic inflammatory response triggers endotoxemia from bacterial translocation of ischemic bowel (if mesenteric involvement) and release of danger-associated molecular patterns (DAMPs) from necrotic tissue.

Thrombotic Causes (45-50% of cases)

• Atherosclerotic arterial disease with in-situ thrombosis at sites of plaque rupture; patients typically have pre-existing peripheral arterial disease, claudication history, or prior revascularization.
• Arterial dissection (spontaneous or traumatic) disrupts normal flow, with intimal flap creating thrombogenic surface; can occur in fibromuscular dysplasia or after blunt trauma.

Embolic Causes (40-45% of cases)

• Cardiac sources account for 80-90% of emboli: atrial fibrillation (most common, 45-50% of cases), left ventricular thrombus post-MI, dilated cardiomyopathy, valvular disease (prosthetic valves, endocarditis), cardiac tumors (myxoma), and paradoxical embolism via patent foramen ovale.
• Arterial sources include atherosclerotic plaque material, arterial aneurysm thrombosis, and atheroma from aortic plaques ("blue toe syndrome").
• Paradoxical embolism occurs when venous thrombus crosses through patent foramen ovale or atrial septal defect to systemic circulation.

Other Causes (5-10%)

• Aortic dissection with dynamic obstruction or static occlusion of arterial branches; associated with sudden severe pain and hemodynamic instability.
• Thrombophilia states including antiphospholipid syndrome, factor V Leiden, prothrombin G20210A mutation, protein C/S deficiency; consider in young patients without atherosclerotic disease.
• Arterial injury from trauma, iatrogenic catheterization complications, compartment syndrome-related compression, or intra-arterial drug injection.
• Hypercoagulable malignancy, nephrotic syndrome, inflammatory bowel disease.

Risk Factors for Acute Ischemia

• Cardiovascular: Atrial fibrillation, recent MI, heart failure, valvular disease, hypertension, diabetes mellitus.
• Vascular: Pre-existing peripheral arterial disease, smoking, hyperlipidemia, prior thrombotic events.
• Patient factors: Age >60, immobilization, recent surgery, antecedent claudication (paradoxically protective as collaterals develop).

Classic "6 P's" of Acute Limb Ischemia (Mnemonic)

• Pain: Sudden onset, severe, disproportionate to examination findings; often the first symptom; may progress to rest pain. Character differs from claudication—present at rest, not reproducibly exercise-induced.
• Pallor: Pale or white appearance of affected limb indicating severely reduced blood flow; may progress to cyanosis or mottling if prolonged.
• Pulselessness: Absent pulses distal to occlusion; early finding before tissue necrosis develops.
• Paresthesias: Tingling, numbness, "pins and needles" sensation from nerve ischemia; indicates developing tissue damage.
• Paralysis: Motor weakness or inability to move affected limb; late finding indicating advanced ischemia and impending tissue necrosis.
• Poikilothermia: Coldness of affected limb compared to contralateral side; reflects decreased perfusion.

Spectrum of Presentation by Rutherford Classification

• Minimal or no sensory loss, no muscle weakness
• Limb not immediately threatened
• Arterial and venous Doppler signals present

• Sensory loss limited to toes, no muscle weakness
• Limb salvageable with prompt intervention
• Arterial Doppler signals absent; venous signals present

• Sensory loss extending above toes, mild muscle weakness
• Immediate intervention required
• Arterial and sometimes venous Doppler signals absent

• Muscle rigidity, sensory loss in entire limb, paralysis
• Major tissue necrosis, muscle infarction
• No arterial or venous Doppler signals
• Amputation inevitable

Physical Examination Findings

• Limb appearance: Pallor (white), then cyanosis (blue-purple), then gangrenous changes (black) with demarcation line.
• Temperature gradient: Sharp demarcation between cold ischemic tissue and warm proximal limb.
• Sensory examination: Determine level of sensory loss (toes only vs. extending proximally); indicates degree of nerve ischemia.
• Motor examination: Test toe plantarflexion and dorsiflexion, ankle plantarflexion/dorsiflexion, knee flexion; paralysis indicates irreversibility.
• Skin changes: Mottling (reticular purple pattern), blistering, tissue necrosis, muscle herniation through fascia (indicates compartment syndrome).
• Associated findings: Look for evidence of cardiac source (irregular heart rate from atrial fibrillation, new cardiac murmur from endocarditis), contralateral pulses (assess for bilateral disease), and signs of other emboli (splinter hemorrhages, Osler nodes, Janeway lesions in endocarditis).

Clinical Assessment and Stratification

• Immediate bedside evaluation using Rutherford classification to determine viability status and urgency of intervention; this classification guides treatment decisions more reliably than any single test.
• Limb viability assessment: Absence of sensory loss and motor paralysis indicates viable limb (Class I); presence of both with muscle rigidity indicates irreversible limb (Class III); intermediate findings guide urgent intervention decisions.

Vascular Studies

• Ankle-brachial index (ABI): Obtained with handheld Doppler if diagnosis unclear; severely reduced or unobtainable ankle pressures confirm ischemia. However, in acute presentation with obvious clinical findings, pursuing ABI delays definitive imaging and intervention.
• Duplex ultrasound: Non-invasive assessment of arterial flow, identifies occlusion level, assesses residual flow distal to occlusion. Limited by operator dependence and inability to visualize heavily calcified vessels. Useful when diagnosis uncertain, but should not delay definitive intervention in obvious acute ischemia.
• Computed tomography angiography (CTA): Rapid, non-invasive imaging defining occlusion location, identifying embolic vs. thrombotic etiology, assessing runoff vessels, and detecting collateral circulation. Excellent for surgical planning when amputation risk assessed. Requires contrast (consider renal function).
• Catheter angiography: Gold standard, provides highest resolution, identifies exact occlusion site, demonstrates runoff and collateral circulation. Allows therapeutic intervention simultaneously (thrombolysis, thrombectomy). Reserved for patients proceeding to intervention as it introduces procedural risk.

Laboratory Studies

• Baseline labs: CBC (baseline for leukocytosis from ischemia-reperfusion), comprehensive metabolic panel (baseline kidney function before contrast/intervention, assess potassium), coagulation studies (PT/INR, PTT, fibrinogen).
• Cardiac workup: Troponin (assess for concurrent MI in embolic cases), ECG (identify atrial fibrillation, acute MI, other arrhythmias indicating cardiac source), echocardiography (assess cardiac structure, identify thrombus, evaluate for endocarditis).
• Thrombus markers: D-dimer elevated but nonspecific; prothrombin time, activated partial thromboplastin time to assess baseline coagulation status.
• Post-intervention labs: Serial creatinine kinase to monitor for rhabdomyolysis; myoglobin and urine myoglobin if rhabdomyolysis suspected; potassium, phosphate monitoring for electrolyte derangements.

Advanced Imaging

• Magnetic resonance angiography (MRA): Excellent soft tissue contrast, no ionizing radiation; slower than CTA, less suitable in acute setting, contraindicated in some implanted devices.
• Infrared thermography: Experimental; identifies tissue viability through temperature gradient assessment.

Diagnostic Criteria for Acute Limb Ischemia

• Sudden onset limb symptoms within hours (not days/weeks as in chronic PAD)
• Hemodynamic significance: Symptomatic reduction in limb blood flow
• Rutherford Class I-III classification based on viability
• Imaging confirmation of arterial occlusion with absent or significantly reduced flow distal to occlusion

Immediate Management (Parallel Procedures)

Anticoagulation

• Unfractionated heparin (UFH): 80-100 units/kg IV bolus, then 18 units/kg/hr continuous infusion; preferred in acute setting as it can be rapidly reversed with protamine if needed, achieves immediate anticoagulation, and is rapidly metabolized. Target activated partial thromboplastin time 1.5-2.5 times normal. Continue throughout hospital course and intervention.
• Alternative: Low-molecular-weight heparin if UFH contraindicated, though less reversible.
• Rationale: Prevents propagation of thrombus beyond occlusion site, reduces distal thromboembolism, prevents recurrent events.

Aggressive Hydration

• Isotonic saline, 200-300 mL/hr IV targeting urine output 200-300 mL/hr; essential to prevent acute kidney injury from rhabdomyolysis and myoglobinuria.
• Alkalinization of urine: Sodium bicarbonate in IV fluids to maintain urine pH >6.5, increasing myoglobin solubility and reducing tubular precipitation.
• Monitor: Strict intake/output, daily weights, serum creatinine/BUN.

1. Surgical Thromboembolectomy (First-line for most embolic cases)

• Mechanism: Direct arterial exposure, removal of thrombus/embolus using Fogarty balloon catheter with intraoperative angiography to confirm vessel patency.
• Indications: Embolic source (Class I-II ischemia with cardiac source), acute thrombosis in native vessel with poor runoff, failed thrombolysis.
• Timing: Within 6-8 hours from symptom onset for best outcomes; technically feasible up to 14-16 hours.
• Advantages: Rapid definitive restoration of flow, immediate assessment of vessel viability, ability to assess for irreversible limb changes.
• Disadvantages: Surgical morbidity, reperfusion injury, requires operative capability on-site.

2. Catheter-Directed Thrombolysis (First-line for in-situ thrombosis in PAD)

• Mechanism: Direct delivery of thrombolytic agent into thrombus, enzymatic dissolution of fibrin.

Agent Selection

• Alteplase (tissue plasminogen activator, tPA): Fibrin-specific, 0.05-0.1 mg/kg/hr; most commonly used, rapid action.
• Urokinase: Non-fibrin-specific, 4000-6000 units/kg/hr; longer infusions typically required.
• Reteplase: Bolus dosing; data limited in peripheral disease.

• Technique: Catheter placed into thrombus with mechanical maceration followed by pharmacologic lysis; typically 4-24 hour infusions with serial angiographic assessment.
• Indications: Viable limb (Class I) with acute thrombosis on chronic PAD, symptom duration <7-14 days, patent distal runoff.
• Advantages: Less invasive, preserves vessel, treats underlying atherosclerotic disease.
• Disadvantages: Delayed restoration of flow (hours), 10-15% bleeding complications (including intracranial hemorrhage), requires ICU monitoring.

3. Hybrid Approach (Increasingly common)

• Catheter-directed thrombolysis followed by balloon angioplasty and/or stenting of underlying lesion, avoiding surgical exposure in appropriate candidates.

4. Amputation

• Indicated in: Class III (irreversible) ischemia with muscle rigidity, sensory loss extending above ankle, myonecrosis.
• Timing: Immediate if signs of irreversibility; delays introduce infection risk and systemic toxicity.
• Level: Through most distal viable tissue; aggressive debridement to viable bleeding tissue.

Specific Medication Management

Antiplatelet Therapy

• Aspirin 325 mg daily started immediately and continued indefinitely to reduce recurrent thromboembolic events.
• Clopidogrel 600 mg loading, then 75 mg daily as alternative if aspirin allergy.

Management of Underlying Cause

• Atrial fibrillation: Anticoagulation with warfarin (target INR 2-3) or direct oral anticoagulant (DOAC) such as apixaban or dabigatran; rate control with beta-blocker or diltiazem.
• Left ventricular thrombus: Anticoagulation with warfarin or DOAC; assess for subsequent thromboembolism risk.
• Endocarditis: Appropriate antibiotics (usually 4-6 weeks); surgical intervention if septic embolism recurs despite anticoagulation.
• Hypercoagulable states: Initiate appropriate anticoagulation; long-term anticoagulation decisions based on thrombophilia workup.

Supportive Care

• Pain management:

Emergencies during and after reperfusion

• Compartment syndrome (true surgical emergency): reperfused muscle swells within a non-compliant fascial envelope, raising interstitial pressure above capillary closing pressure and causing ongoing ischemia despite a patent artery. Signals: pain out of proportion, pain on passive stretch of the compartment, tense "woody" calf, and rising creatine kinase. A palpable distal pulse does not exclude it — arterial inflow persists long after capillary perfusion has failed. Compartment pressure within ~30 mmHg of diastolic pressure (delta pressure <30 mmHg) supports immediate four-compartment fasciotomy.
• Reperfusion syndrome / rhabdomyolysis: washout of potassium, hydrogen ion, phosphate, and myoglobin from necrotic myocytes. Signals: peaked T waves and wide QRS on ECG, metabolic acidosis, tea-colored urine with heme-positive dipstick but few RBCs on microscopy. Hyperkalemic cardiac arrest at the moment of unclamping is the classic lethal event; treat with IV calcium, insulin/dextrose, and potassium removal per standard hyperkalemia care.
• Acute kidney injury: myoglobin cast nephropathy plus contrast exposure and hypovolemia; recognized by rising creatinine and falling urine output, staged by KDIGO criteria. Nephrology consultation and dialysis if refractory hyperkalemia or acidosis.

Complications of the limb and the intervention

• Limb loss: irreversible myonecrosis (Rutherford III) mandates amputation; rigid, mottled, non-blanching muscle with fixed staining is the signal.
• Bleeding from thrombolysis: the feared event is intracranial hemorrhage — any new headache, seizure, or focal deficit during infusion means stop the lytic and obtain emergent head CT. Access-site and retroperitoneal hematoma present with flank/back pain and unexplained hypotension.
• Catheter/Fogarty-related arterial injury: intimal dissection, pseudoaneurysm (pulsatile mass with bruit), or arteriovenous fistula (continuous machinery murmur).
• Recurrent occlusion: signaled by return of pain and loss of a previously restored pulse; reflects untreated atherosclerotic lesion or inadequate anticoagulation.
• Heparin-induced thrombocytopenia: platelet fall days into heparin with new thrombosis — stop all heparin, start a non-heparin anticoagulant.
• Infection and sepsis from necrotic tissue; chronic pain, neuropathy, and claudication are common survivorship outcomes. The 2016 AHA/ACC lower extremity PAD guideline emphasizes long-term surveillance and risk-factor therapy after limb salvage.

• **The 6 P's are the stem's giveaway**: pain, pallor, pulselessness, paresthesia, paralysis, poikilothermia. Pain and pallor come first; paresthesia and paralysis are late and mean the limb is threatened, not merely ischemic.
• Sudden onset + atrial fibrillation + no prior claudication + normal contralateral pulses = embolus, most often lodging at a bifurcation (common femoral is classic). Gradual onset, prior claudication, and abnormal contralateral pulses point to in-situ thrombosis on chronic atherosclerosis.
• Single best next step in almost every stem: IV unfractionated heparin plus emergent vascular surgery consultation. Anticoagulation prevents thrombus propagation and does not commit the patient to any one revascularization strategy. The 2016 AHA/ACC PAD guideline frames ALI as requiring emergent evaluation of limb viability, with revascularization for any salvageable limb.
• Classification drives therapy, not imaging: Rutherford I/IIa can tolerate catheter-directed thrombolysis; IIb (sensory loss above the toes plus motor weakness) needs immediate open surgical thromboembolectomy because lysis takes hours the limb does not have; III (rigid muscle, fixed mottling, no Doppler signals) goes to primary amputation — revascularizing a dead limb can kill the patient by hyperkalemia and myoglobinuric renal failure.
• Do not delay definitive care for testing. Ordering ABI, MRA, or a formal duplex before consulting surgery is the classic wrong answer in a mottled, pulseless, insensate limb.
• The examiners' favorite post-op twist: worsening pain and a tense compartment with a palpable pulse after successful revascularization — this is compartment syndrome, and the answer is fasciotomy, not repeat angiography.
• Watch the labs after flow returns: rising creatine kinase, peaked T waves, tea-colored urine — reperfusion rhabdomyolysis. Volume-load with isotonic fluid and treat hyperkalemia before it becomes an arrest rhythm.
• Common distractor: phlegmasia cerulea dolens from massive DVT also produces a painful, cyanotic, pulse-poor leg — but it is swollen and engorged, whereas ALI is pale, cool, and non-edematous.